Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration
This retrospective real-world study confirmed the clinical benefit of durvalumab plus chemotherapy in treatment-naïve ABC patients. Peripheral sPD-L1 and CSF1R are promising prognostic biomarkers for this therapeutic strategy. Presence of ADGRB3 or RNF43 mutations could improve the stratification of immunotherapy outcomes, but further studies are warranted to explore the underlying mechanisms.
Authors
- Zixian Wang (ORCID: https://orcid.org/0000-0002-7950-787X)
- Chuqiao Liang (ORCID: https://orcid.org/0009-0003-1223-5448)
- Wen Zhou (ORCID: https://orcid.org/0000-0002-5496-5815)
- Miao‐Zhen Qiu (ORCID: https://orcid.org/0000-0002-4774-6235)
- Dongsheng Zhang (ORCID: https://orcid.org/0000-0001-9633-8521)
- Zhiqiang Wang
- Fenghua Wang (ORCID: https://orcid.org/0000-0002-2443-8360)
- Jianwen Chen (ORCID: https://orcid.org/0000-0003-1904-2676)
- Hui Luo (ORCID: https://orcid.org/0000-0001-6312-9299)
- Shengping Li (ORCID: https://orcid.org/0000-0002-2698-2757)
- Bing Bai (ORCID: https://orcid.org/0000-0002-1306-5343)
- Yun‐Xin Lu
- Furong Liu (ORCID: https://orcid.org/0000-0002-4806-1254)
- Xiaoli Wei (ORCID: https://orcid.org/0000-0002-9284-3237)
- Peidong Chi (ORCID: https://orcid.org/0000-0002-9838-2590)
- Yuhong Li (ORCID: https://orcid.org/0000-0002-3769-6772)
- Yin Jin (ORCID: https://orcid.org/0009-0001-6108-0214)
- Man Nie
- Yang Zhang
- Yu Liu
- Yun Wang (ORCID: https://orcid.org/0009-0006-5841-3627)
- Feng Wang (ORCID: https://orcid.org/0009-0005-8775-4925)
- Guifang Guo (ORCID: https://orcid.org/0000-0003-1197-1147)
Institutions
- Sun Yat-sen University (CN)
- Jiangsu Province Science and Technology Department (CN)
- Sun Yat-sen University Cancer Center (CN)
- Guangdong Provincial People's Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1007/s00262-024-03796-1
- Citations
- 4
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.29
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province